Sort
21,453 grants matching “tuberculosis”
ANALYSIS OF CHEMICAL STRUCTURES AND THERAPEUTIC ACTIVITY OF AGENTS FOR HIV AND TUBERCULOSIS (CHEMDB)
$590,866Rocco Casagrande · Gryphon Scientific, Llc · N01 · FY2017 · AI
Biology and Biosignatures of Anti-Tuberculosis Treatment Response
$590,863John T Belisle · Colorado State University · U01 · FY2019 · AI
Mtb strain-dependent mechanisms of pathogenesis in mouse models
$590,820Kevin B Urdahl · University Of Washington · U19 · FY2021 · AI
Real-time surveillance to support dynamic and predictive models of MDR/XDR TB
$590,760Megan B Murray · Brigham And Women'S Hospital · U19 · FY2009 · AI
Mechanisms of Innate Immune Evasion by Mycobacterium Tuberculosis
$590,755Jennifer A Philips · Washington University · R01 · FY2025 · AI
Design, Syntheses and Studies of Novel Antituberculosis Agents
$590,748Marvin J Miller · University Of Notre Dame · R37 · FY2021 · AI
Mapping eQTLs that affect susceptibility to Tuberculosis
$590,585Yoav Gilad · University Of Chicago · R01 · FY2012 · AI
Validation of urine/serum LAM in HIV/nonHIV TB suspects and POC Test Development
$590,576Delphi Chatterjee · Colorado State University · R01 · FY2019 · AI
Harnessing activated CD4 T cells to define new mechanisms of protection in tuberculosis
$590,248Tyler Dallas Bold · University Of Minnesota · R01 · FY2025 · AI
Harnessing activated CD4 T cells to define new mechanisms of protection in tuberculosis
$590,248Tyler Dallas Bold · University Of Minnesota · R01 · FY2023 · AI
Harnessing activated CD4 T cells to define new mechanisms of protection in tuberculosis
$590,248Tyler Dallas Bold · University Of Minnesota · R01 · FY2024 · AI
A robust platform for multiplexed, subcellular proteomic imaging in human tissue
$590,000Robert Michael Angelo · Stanford University · UH3 · FY2019 · CA
PS05-003, TUBERCULOSIS ELIMINATION AND LABORATORY
$589,469Susan Jenkins · Missouri State Dept Of Social Services · U52 · FY2007 · PS
Role of IL-17 Cytokine Networks in TB Relapse Due to HIV
$589,202Janice J Endsley · University Of Texas Med Br Galveston · R01 · FY2022 · AI
Mycobacterial Lung Diseases in Virginia: sequencing and clinical determinants of relapse and outcome
$589,122Eric R Houpt · University Of Virginia · R01 · FY2025 · HL
Optimizing vaccine science to improve the outcome of tuberculosis treatment
$589,119Selvakumar Subbian · Rutgers Biomedical And Health Sciences · R01 · FY2025 · AI
Coronary Atherosclerosis and Immune Activation in HIV and Tuberculosis Infection
$589,109Moises Arturo Huaman Joo · University Of Cincinnati · R01 · FY2025 · HL
Novel Inhibitors to DHPS to Probe Catalytic Mechanism & Therapeutic Potential
$589,007Stephen W White · St. Jude Children'S Research Hospital · R01 · FY2007 · AI
Shaping Next Generation Aminoglycoside Antibiotics for Treatment of Multidrug-Resistant Diseases
$588,996David Crich · University Of Georgia · R01 · FY2025 · AI
Infectious Disease/Basic Microbial Pathogenic Mechanisms
$588,918Daniel E Goldberg · Washington University · T32 · FY2016 · AI
Molecular basis of heme scavenging by Gram-positive bacteria
$588,730Robert Thompson Clubb · University Of California Los Angeles · R01 · FY2025 · AI
PROJECT 2: Determine clinically relevant host-viral dependency networks for respiratory infections including SARS-CoV-2
$588,642Melanie Maria Ott · University Of California, San Francisco · U19 · FY2024 · AI
Dynamics of TB and MDR TB transmission in areas with high HIV prevalence
$588,492Nicola Mario Zetola · University Of Pennsylvania · R01 · FY2014 · AI
TB Aftermath
$588,454Jonathan E Golub · Johns Hopkins University · R01 · FY2025 · AI
The Impact of Diabetes on TB treatment outcomes
$588,329Jonathan E Golub · Johns Hopkins University · R01 · FY2016 · AI